Proteon Therapeutics Inc (NASDAQ:PRTO) has been given a consensus recommendation of “Hold” by the nine research firms that are currently covering the firm. Seven equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $3.40.
PRTO has been the subject of several analyst reports. Zacks Investment Research raised shares of Proteon Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Tuesday, March 21st. Maxim Group reissued a “buy” rating and set a $6.00 price target on shares of Proteon Therapeutics in a report on Thursday, March 16th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Proteon Therapeutics in a report on Tuesday, January 17th. HC Wainwright cut shares of Proteon Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $18.00 to $3.00 in a report on Friday, March 17th. Finally, Robert W. Baird reissued a “neutral” rating and set a $3.00 price target on shares of Proteon Therapeutics in a report on Thursday, March 16th.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Spark Investment Management LLC bought a new position in shares of Proteon Therapeutics during the third quarter valued at $107,000. Perceptive Advisors LLC bought a new position in shares of Proteon Therapeutics during the fourth quarter valued at $635,000. Pharmstandard International S.A. bought a new position in shares of Proteon Therapeutics during the fourth quarter valued at $2,214,000. Finally, Baker BROS. Advisors LP bought a new position in shares of Proteon Therapeutics during the third quarter valued at $2,786,000. Institutional investors own 49.28% of the company’s stock.
Shares of Proteon Therapeutics (NASDAQ:PRTO) traded down 3.03% during midday trading on Tuesday, reaching $1.60. The company’s stock had a trading volume of 22,755 shares. The stock’s 50 day moving average price is $1.66 and its 200 day moving average price is $4.60. Proteon Therapeutics has a one year low of $1.40 and a one year high of $11.63. The firm’s market cap is $26.56 million.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.